Presenting on Emerging Growth Conference 88 Day 2 on December 11; Register to live stream
Globe Newswire (Wed, 10-Dec 7:00 AM ET)
Clene to Present at the Emerging Growth Conference
Globe Newswire (Tue, 9-Dec 8:30 AM ET)
Presenting on Emerging Growth Conference 88 Day 1 on December 10; Register to live stream
Globe Newswire (Tue, 9-Dec 7:00 AM ET)
Statistically Significant ALS Biomarker Results Boost CNM-Au8’s Accelerated Approval Prospects
Market Chameleon (Wed, 3-Dec 3:58 AM ET)
Globe Newswire (Wed, 3-Dec 8:00 AM ET)
Clene to Provide CNM-Au8 ALS Program Update
Globe Newswire (Tue, 2-Dec 5:39 PM ET)
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
Globe Newswire (Thu, 20-Nov 8:00 AM ET)
Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights
Globe Newswire (Thu, 13-Nov 8:00 AM ET)
Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream
Globe Newswire (Wed, 22-Oct 7:00 AM ET)
Presenting on Emerging Growth Conference 87 Day 1 on October 22. Register to live stream.
Globe Newswire (Tue, 21-Oct 7:00 AM ET)
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Clene trades on the NASDAQ stock market under the symbol CLNN.
As of December 18, 2025, CLNN stock price declined to $6.39 with 51,620 million shares trading.
CLNN has a beta of 1.99, meaning it tends to be more sensitive to market movements. CLNN has a correlation of 0.07 to the broad based SPY ETF.
CLNN has a market cap of $66.03 million. This is considered a Micro Cap stock.
Last quarter Clene reported $15,000 in Revenue and -$.85 earnings per share. This fell short of revenue expectation by $-50,084 and missed earnings estimates by -$.27.
In the last 3 years, CLNN traded as high as $39.80 and as low as $2.28.
The top ETF exchange traded funds that CLNN belongs to (by Net Assets): VTI, VXF.
CLNN has outperformed the market in the last year with a return of +46.6%, while the SPY ETF gained +13.4%. In the last 3 month period, CLNN beat the market returning +3.6%, while SPY returned +3.2%. However, in the most recent 2 weeks CLNN has underperformed the stock market by returning -11.5%, while SPY returned -0.8%.
CLNN support price is $5.98 and resistance is $7.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLNN shares will trade within this expected range on the day.
